

HPV Vaccine Session

Lauri Markowitz, MD
NCHHSTP, CDC

Advisory Committee on Immunization Practices
Atlanta, GA

October 22, 2008



DEPARTMENT OF HEALTH AND HUMAN SERVICES
CENTERS FOR DISEASE CONTROL AND PREVENTION



Outline of HPV Session

- Overview of upcoming policy issues and updates
- National Provider Survey
- Post Licensure Vaccine Safety

Upcoming HPV Vaccine Policy Issues

Policy Issue	Earliest Vote Date
Quadrivalent vaccine in females >26 yrs	Feb 2009
Bivalent vaccine in females	June/Oct 2009
Quadrivalent vaccine in males	Oct 2009

HPV Vaccine Policy Issues

- June 2008 ACIP meeting - Quadrivalent vaccine in females >26 yrs
 - Clinical trial data – interim results
 - Overview of epidemiology
 - Cost effectiveness (CE) models
 - Proposed recommendation: permissive, but no extension of catch-up over age 26 yrs

Current Plan:

Await FDA licensure

Review CE models

Re-discuss recommendations with ACIP in 2009

Other Updates

- The FDA originally approved quadrivalent vaccine in 2006 for females ages 9 to 26 yrs for prevention of 6,11,16,18 related
 - Cervical cancer
 - Precancerous cervical, vaginal and vulvar lesions
 - Genital warts
- Label changed to include prevention of vaginal and vulvar cancers (Sept 2008)


HPV Vaccine Implementation in the US

ACIP and VFC vote - June 2006

VFC contract - Oct 2006

All states have VFC vaccine - March 2007

Percent of States/Programs Providing HPV Vaccine for VFC and Underinsured Population (<19 yrs)



*Jan 2008, 15 months after VFC contract established

Source: Association of Immunization Managers


HPV Vaccine Implementation

- Quadrivalent HPV vaccine doses distributed in U.S. through Sept 2008*
>20 million
- Coverage with ≥ 1 dose (4th quarter 2007)[#]
25% among 13-17 year-old females

*Data from manufacturer

[#] National Immunization Survey. MMWR 2008;57

Estimated ≥ 1 Dose HPV Vaccine Coverage*, Females 13-17 Years, 2007



* With at least one dose

National Immunization Survey. MMWR 2008;57

Outline of HPV Session

- National Provider Survey Dr. Matt Daley
- Post Licensure Vaccine Safety Data
 - VAERS Dr. Angela Calugar
 - Case series/CISA Dr. Barbara Slade
 - Vaccine Safety Datalink Julianne Gee
 - Summary Dr. John Iskander

 - Pregnancy Registry Dr. Adrian Dana